<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01219140</url>
  </required_header>
  <id_info>
    <org_study_id>POM 2010-001</org_study_id>
    <nct_id>NCT01219140</nct_id>
  </id_info>
  <brief_title>Pomegranate Extract Biomarker Study in Osteopenic Women</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial to Evaluate the Safety and Efficacy of Pomegranate Extract Capsules in Post-Menopausal Subjects With Decreased Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>POM Wonderful LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>POM Wonderful LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of post-menopausal subjects (with decreased bone mineral density) with pomegranate
      extract capsules will produce statistically significant changes in biomarkers for bone
      resorption and formation when compared to subjects receiving placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>Throughout study</time_frame>
    <description>To evaluate the impact of pomegranate extract capsules on urinary N-terminal telopeptide (NTX) and serum procollagen type 1 amino-terminal propeptide (P1NP), in post-menopausal women with decreased bone mineral density</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Throughout study</time_frame>
    <description>Incidence of adverse events Changes in vital signs or laboratory values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Osteopenic Women</condition>
  <arm_group>
    <arm_group_label>2 POMx Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 POMx Capsules daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 placebo Capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo Capsules daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>2 POMx Capsules</intervention_name>
    <description>2 POMx Capsules daily</description>
    <arm_group_label>2 POMx Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>2 placebo Capsules</intervention_name>
    <description>2 placebo Capsules daily</description>
    <arm_group_label>2 placebo Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women (having had their last menstrual period within the past 15 years
             and an appropriate serum FSH value) 45-65 years of age;

          -  The subject must have a T score of -1 to -2.5 at the lumbar spine or proximal femur;

          -  All clinical safety laboratory values at screening and randomization must be either
             within the reference range or be determined by the investigator and the sponsor to be
             abnormal, but not clinically significant;

          -  The patient must have provided written informed consent.

        Exclusion Criteria:

          -  The subject has any of the following conditions: connective tissue disease, history of
             clinically significant renal, hepatic pulmonary, cardiovascular, cerebrovascular,
             gastrointestinal, metabolic, hematological, endocrinological, urological,
             immunological, neurologic or psychiatric disorders, unless approved by the sponsor on
             a case by case basis;

          -  The subject has a positive test result for Hepatitis B surface antigen or antibody to
             hepatitis C virus at Screening;

          -  The subject has a known history of infection with the human immunodeficiency virus
             (HIV); -

          -  The subject has used bisphosphonate or fluoride therapy within the past 12 or 24
             months, respectively;

          -  The subject has used denosumab within the past 24 months;

          -  The subject has used tibolone, parathyroid hormone (or any of its derivatives),
             systemic glucocorticoids or inhaled glucocorticoids, anabolic steroids or testosterone
             within the past 6 months;

          -  The subject has used estrogens, selective estrogen receptor modulators, calcitonin or
             calcitriol within the past 3 months;

          -  The subject has hyperparathyroidism, hypoparathyroidsim, hyperthyroidism,
             hypothyroidism, hypocalcemia, rheumatoid arthritis, paget's disease of bone,
             osteomalacia;

          -  The subject has had a bone fracture within the past year;

          -  The subject has acute or chronic disease requiring frequent changes in medications or
             dosages of chronic therapy;

          -  A history of alcoholism within the last 2 years or a current history of imbibing 3 or
             more units of alcohol per day. (1 unit is equivalent to 1 glass of wine, 1 pint of
             beer, or 1 shot of hard liquor);

          -  The subject has participated in another study with an investigational drug or device
             during the 30 days prior to study entry;

          -  The subject has a condition interfering with his ability to provide informed consent
             or comply with study instructions, or the patient has a condition, which might
             confound the interpretation of the study result;

          -  The subject has a condition endangering herself if she were to participate in this
             trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SeaView Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>October 8, 2010</last_update_submitted>
  <last_update_submitted_qc>October 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>POM Wonderful LLC</name_title>
  </responsible_party>
  <keyword>POMx</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>postmenopausal women</keyword>
  <keyword>Pomegranate</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

